Table 1

Cost effectiveness in net costs per major outcome averted (in US$) for Amsterdam (Netherlands) of two screening strategies for asymptomatic Chlamydia trachomatis (women aged 15–25 and women aged 15–40), in the baseline, assuming high performance testing*, pooling†, and both

Women aged (years)
15–2515–40
*PCR testing with sensitivity of 98.8% and specificity of 99.9%4; †pooling of urine specimens by five with relative sensitivity and specificity of 100%.5
Baseline1110015800
High performance testing890012400
Pooling48006800
High performance testing and pooling37005200